

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
38402	16/SC/0653	215441	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Number Agreed	5	5	Date Agreed	30/04/2018	2	27/04/2018	2	Recruitment Finished	Screen failures
38403	14/SC/1161	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	100	100	Date Agreed	03/08/2018	170	03/05/2018	170	Recruitment Finished	Target Met
38404	16/NW/0600	140502	European multicenter retrospective-prospective cohort study to observe Safinamide safety profile and pattern of use in clinical practice during the first post-commercialization phase? Study Z7219N02	Number Agreed	7	7	Date Agreed	31/05/2018	7	01/06/2018	7	Recruitment Finished	Target Met
38405	16/EM/0133	184873	A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis	Number Agreed	3	3	Date Agreed	30/06/2018	2	20/06/2018	2	Recruitment Finished	target not met due to tight exclusion criteria and despite multiple screenings
38406	15/ES/0166	186845	Assessment of Stelara? (ustekinumab) and other biologic therapies in patients with psoriatic arthritis in the normal health-care practice. A prospective, observational cohort PsA Bio Study	Number Agreed	11	11	Date Agreed	30/06/2018	11	30/06/2018	11	Recruitment Finished	Target Met
38407	17/EE/0422	230642	A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis	Number Agreed	1	1	Date Agreed	10/09/2018	1	10/09/2018	1	Recruitment Finished	Target Met
38408	15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	3	3	Date Agreed	31/10/2018	2	08/10/2018	2	Withdrawn By Sponsor	18 further patients considered but either failed pre-screening or declined participation?

38409	17/EE/0196	218606	Long-term observational, prospective study to collect in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficiency of secukinumab in adult patients with moderate to severe plaque psoriasis.	Number Agreed	10	10	Date Agreed	12/10/2019	19	12/10/2018	19	Recruitment Finished	Target Met
38410	14/SC/1366	135118	EPOCH: A Phase III Clinical Trial Evaluating TheraSphere? in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy	Number Agreed	2	2	Date Agreed	01/10/2018	1	12/10/2018	1	Recruitment Finished	Rare patient group
38411	17/SW/0279	231649	A Phase III/IV, single arm, multicentre study of atezolizumab (Tecentriq) to investigate long-term safety and efficacy in previously-treated patients with locally advanced or metastatic non-small cell lung cancer (TAIL)	Number Agreed	5	5	Date Agreed	15/04/2019	4	24/10/2018	4	Withdrawn By Sponsor	Recruitment closed earlier than anticipated.
38412	16/WM/0317	206807	Randomized Efficacy and Safety Trial with Oral S44819 after recent ischaemic cerebral event.International, multi-centre, randomized, double-blind placebo-controlled phase II study.	Number Agreed	10	10	Date Agreed	31/12/2018	13	15/11/2018	13	Recruitment Finished	Target met
38413	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (C	Number Agreed	2	2	Not Available / Not Agreed		0	15/01/2019	0	Withdrawn By Host	Declined by site
38414	16/LO/0877	202257	A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB* (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WHO COMPLETED FIRST-LINE CHEMOTHERAPY FOR UNRESECTABLE LOCALLY ADVANC	Number Agreed	2	2	Date Agreed	28/02/2019	1	21/02/2019	1	Recruitment Finished	Rare patient group
38415	17/EE/0497	238458	A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE)	Number Agreed	4	4	Date Agreed	20/12/2019	0	25/02/2019	0	Withdrawn By Sponsor	Recruitment closed earlier than anticipated